Loading organizations...

§ Venture Capital · United Kingdom
Venture capital firm investing in early-stage technology, life sciences, and renewable energy companies using UK EIS funds.
Deepbridge Capital is a venture capital firm based in Chester, England, that invests in early-stage technology, life sciences, and renewable energy companies. The firm primarily deploys capital through the United Kingdom's Enterprise Investment Scheme and Estate Planning Service funds to support targeted asset-backed projects and growth-stage commercial businesses. Operating with a team of 53 employees across additional offices in London, Edinburgh, Bristol, and Queensland, Australia, the organization manages approximately $370.6 million in total assets. Deepbridge Capital has invested in 71 Enterprise Investment Scheme companies and 63 Seed Enterprise Investment Scheme companies, backing portfolio businesses such as Zilico, vTime, and Voxpopme. By late October 2021, the firm had exceeded £200 million in deployed funds with a net asset value surpassing the £250 million financial milestone. Deepbridge Capital was officially founded in 2010 by managing partner Ian Warwick.
Key people at Deepbridge Capital.
Key people at Deepbridge Capital.
Deepbridge Capital is a UK-based venture capital and investment management firm specializing in growth capital for technology, life sciences, and asset-backed renewable energy projects. Their mission is to partner with innovative and committed management teams to help UK-based companies realize their potential and become leading-edge businesses, aiming to deliver optimal returns to investors. They focus on supporting early-stage and growth companies, particularly in sectors such as biotechnology, medical technology, software, and renewable energy, thereby playing a significant role in nurturing innovation within the UK startup ecosystem[1][2][6].
Founded in 2010 and headquartered in Chester, Deepbridge Capital was established to provide private investors access to carefully sourced and managed investment opportunities. The firm has evolved to deploy over £200 million across its funds, including Enterprise Investment Scheme (EIS) funds focused on life sciences and renewable energy. Key partners and sector specialists at Deepbridge work closely with portfolio companies throughout their funding journey, emphasizing long-term growth and suitable exit strategies. Their portfolio includes companies like Sky Medical Technology, Thalia Design Automation, and Touch Biometrix, reflecting a strong focus on health tech and software innovation[1][2][3][4].
Deepbridge Capital rides the growing trend of specialized venture capital focused on high-impact sectors like life sciences and renewable energy, which are critical for addressing global health challenges and climate change. The timing aligns with increasing investor interest in sustainable and technology-driven innovation, supported by UK government incentives such as the EIS. By channeling capital into early-stage companies with strong management teams, Deepbridge helps accelerate the commercialization of cutting-edge technologies, thereby strengthening the UK’s position in these strategic industries and fostering a vibrant innovation ecosystem[1][3][6].
Looking ahead, Deepbridge Capital is likely to continue expanding its investments in technology and renewable energy sectors, capitalizing on rising demand for sustainable solutions and advanced healthcare technologies. Trends such as digital health, biotech innovation, and green energy transition will shape their portfolio focus. Their influence may grow as they deepen partnerships with innovative startups and investors, potentially increasing their role in shaping the UK’s tech growth landscape and contributing to global sustainability goals. This trajectory aligns with their mission to support pioneering companies and deliver strong returns to investors while driving impactful innovation[1][3][6].
Deepbridge Capital has 11 tracked investments across 9 companies. The latest tracked deal is $6.0M Series U in IbisVision in May 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2023 | IbisVision | $6.0M Series U | — | Richard Thompson |
| Mar 1, 2023 | GenoMe Diagnostics | $2.0M Seed | — | — |
| Apr 1, 2022 | Ceryx Medical | $5.0M Seed | — | Parkwalk Advisors, Richard Thompson |
| Jan 20, 2022 | Aegiq | $2.5M Seed | Gernot Berger | — |
| Dec 1, 2021 | Glucose Republic | $660K Seed | — | — |
| Sep 1, 2021 | Ferryx | $420K Seed | — | — |
| Apr 1, 2019 | Touch Biometrix | $3.0M Series A | — | — |
| May 1, 2018 | Touch Biometrix | $200K Seed | — | — |
| Aug 1, 2017 | Sky Medical Technology | $14.0M Series B | — | — |
| Feb 1, 2017 | VoxSmart | $7.0M Series A | Deepbridge Capital | — |
| Jan 1, 2015 | Sky Medical Technology | $15.0M Series A | — | — |